Molecular Cancer apeutics apeutic Discovery A Induction by FoxO 3 a Mediates the Anticancer ivities of the Broad-Range Kinase Ther bitor UCN-01

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• The hallmarks of cancer

  2012cited by this paper
• PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cells

  2009cited by this paper
• Defective p 53 signaling in p 53 wild-type tumors attenuates p 21 waf 1 induction and cyclin B repression rendering them sensitive to Chk 1 inhibitors that abrogate DNA damage-induced S and G 2 arrest

  2008cited by this paper
• PUMA, a potent killer with or without p53

  2008cited by this paper
• PUMA regulates intestinal progenitor cell radiosensitivity and gastrointestinal syndrome.

  2008cited by this paper
• Sp1 and p73 activate PUMA following serum starvation.

  2008cited by this paper
• Targeting Checkpoint Kinase 1 in Cancer Therapeutics

  2007cited by this paper
• Apoptosis Induction in Human Melanoma Cells by Inhibition of MEK Is Caspase-Independent and Mediated by the Bcl-2 Family Members PUMA, Bim, and Mcl-1

  2007cited by this paper
• SMAC/Diablo mediates the proapoptotic function of PUMA by regulating PUMA-induced mitochondrial events

  2007cited by this paper
• The nuclear function of p53 is required for PUMA-mediated apoptosis induced by DNA damage

  2007cited by this paper
• A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib.

  2007cited by this paper
• p53 independent induction of PUMA mediates intestinal apoptosis in response to ischaemia–reperfusion

  2006cited by this paper
• The aPKC–PAR-6–PAR-3 cell polarity complex localizes to the centrosome attracting body, a macroscopic cortical structure responsible for asymmetric divisions in the early ascidian embryo

  2006cited by this paper
• FOXO3a-dependent regulation of Puma in response to cytokine/growth factor withdrawal

  2006cited by this paper
• Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways

  2006cited by this paper
• The Cyclin-Dependent Kinase Inhibitor UCN-01 Plus Cisplatin in Advanced Solid Tumors: A California Cancer Consortium Phase I Pharmacokinetic and Molecular Correlative Trial

  2005cited by this paper
• Farnesyltransferase Inhibitor BMS-214662 Induces Apoptosis in Myeloma Cells through PUMA Up-Regulation, Bax and Bak Activation, and Mcl-1 Elimination

  2005cited by this paper
• Pharmacological manipulation of cell death: clinical applications in sight?

  2005cited by this paper
• Blockage of cyclin cdk's, PKC and phosphoinositol 3-kinase pathways leads to augmentation of apoptosis in drug-resistant leukemia cells: evidence for interactive effects of flavopiridol, LY 294002, roscovitine,wortmannin and UCN-01.

  2005cited by this paper
• Cell-cycle targeted therapies.

  2004cited by this paper
• SMAC/Diablo-dependent apoptosis induced by nonsteroidal antiinflammatory drugs (NSAIDs) in colon cancer cells.

  2004cited by this paper
• NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS

  2004cited by this paper
• Implications of p53 in growth arrest and apoptosis on combined treatment of human Mammary epithelial cells with topotecan and UCN-01.

  2004cited by this paper
• Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways.

  2003cited by this paper
• PUMA mediates the apoptotic response to p53 in colorectal cancer cells

  2003cited by this paper
• Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) promotes mitochondrial dysfunction and apoptosis induced by 7-hydroxystaurosporine and mitogen-activated protein kinase kinase inhibitors in human leukemia cells that ectopically express Bcl-2 and Bcl-xL.

  2003cited by this paper
• Puma is an essential mediator of p53-dependent and -independent apoptotic pathways.

  2003cited by this paper
• Combined antitumor activity of 7-Hydroxystaurosporine (UCN-01) and Tamoxifen against human breast carcinomain Vitro andin Vivo

  2003cited by this paper
• Interruption of the NF-B pathway by Bay 11-7082 promotes UCN-01 – mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells

  2003cited by this paper
• Inhibitors of MEK1/2 Interact with UCN-01 to Induce Apoptosis and Reduce Colony Formation in Mammary and Prostate Carcinoma Cells

  2002cited by this paper
• Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism.

  2002cited by this paper
• Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine)

  2002cited by this paper
• UCN-01 (7-Hydroxystauorsporine) Blocks PMA-Induced Maturation and Reciprocally Promotes Apoptosis in Human Myelomonocytic Leukemia Cells (U937)

  2002cited by this paper
• Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27(KIP1).

  2002cited by this paper
• Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells.

  2001cited by this paper
• UCN‐01 selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/or G2 checkpoint abrogation

  2000cited by this paper
• Pharmacokinetics and pharmacodynamics of a novel protein kinase inhibitor, UCN-01

  1999cited by this paper

• No citing papers are available for this paper.